6-Deoxy-6-((2-carboxyethyl)sulfinyl)-heptakis(6-deoxy-6-(2-carboxyethyl)thio)-gamma-cyclodextrin Epimer B

Product Description

6-Deoxy-6-((2-carboxyethyl)sulfinyl)-heptakis(6-deoxy-6-(2-carboxyethyl)thio)-gamma-cyclodextrin Epimer B
Catalog number: B2027387
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 mg
Molecular Weight or Concentration: NA
Supplied as: Chemicals
Storage: −80°C
Keywords: Sugammadex Impurity B, Sugammadex Sulfoxide Epimer B

References:
1. Bom, A., Bradley, M., Cameron, K., Clark, J. K., Van Egmond, J., Feilden, H., … & Zhang, M. Q. (2002). A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic receptor. Angewandte Chemie International Edition, 41(2), 265-270.
2. Welliver, M. (2006). New drug review: Sugammadex: A selective relaxant binding agent. AANA Journal, 74(5), 387-393.
3. Yang, L. P., & Keam, S. J. (2009). Sugammadex: a review of its use in anaesthesiology. Drugs, 69(7), 919-942.
4. Nicholson, W. T., Sprung, J., & Jankowski, C. J. (2007). Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 27(8), 1181-1188.
5. Gijsenbergh, F., Ramael, S., Houwing, N., & van Iersel, T. (2005). First human exposure to sugammadex, a new reversal agent for neuromuscular block induced by rocuronium or vecuronium. Anesthesiology, 103(4), 711-717.
6. Zhang, M. Q. (2003). Drug-specific cyclodextrins: the future of rapid reversal of neuromuscular blockade?. Current Opinion in Anaesthesiology, 16(4), 389-395.
7. Tarver, A. L., & Chatterjee, S. (2010). Sugammadex: a breakthrough in neuromuscular blockade reversal. Expert Opinion on Biological Therapy, 10(6), 985-993.
8. Naguib, M. (2007). Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesthesia & Analgesia, 104(3), 575-581.
9. Adam, J. M., Bennett, D. J., Breckenridge, R. J., Cameron, K., Clark, J. K., & Zhang, M. Q. (2002). Cyclodextrin derivatives as specific reversing agents for neuromuscular blockade. Bioorganic & Medicinal Chemistry Letters, 12(18), 2639-2642.
10. Peeters, P. A., van den Heuvel, M. W., van Heumen, E., Passier, P. C., Smeets, J. M., & van Iersel, T. (2010). Safety, tolerability and pharmacokinetics of sugammadex using a range of doses in healthy male volunteers. British Journal of Clinical Pharmacology, 70(5), 670-679.
6-Deoxy-6-((2-carboxyethyl)sulfinyl)-heptakis(6-deoxy-6-(2-carboxyethyl)thio)-gamma-cyclodextrin Epimer B

Products Related to 6-Deoxy-6-((2-carboxyethyl)sulfinyl)-heptakis(6-deoxy-6-(2-carboxyethyl)thio)-gamma-cyclodextrin Epimer B can be found at Powder